OLYSIO

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg

Pieejams no:

Janssen-Cilag (New Zealand) Ltd

SNN (starptautisko nepatentēto nosaukumu):

Simeprevir sodium 154.4 mg (equivalent to simeprevir 150.0 mg)

Deva:

150 mg

Zāļu forma:

Capsule

Kompozīcija:

Active: Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Gelatin Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Sodium laurilsulfate

Receptes veids:

Prescription

Ražojis:

Janssen Pharmaceutica NV

Ārstēšanas norādes:

Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection.

Produktu pārskats:

Package - Contents - Shelf Life: Blister pack, PVC-PE-PVDC blister & Al push-through foil - 7 capsules - 24 months from date of manufacture stored at or below 30°C protect from light - Blister pack, PVC-PE-PVDC blister & Al push-through foil - 28 capsules - 24 months from date of manufacture stored at or below 30°C protect from light

Autorizācija datums:

2013-09-02